42 CFR 81.21
§ 81.21 Cancers requiring the use of NIOSH-IREP.
United States · 42 CFR — Public Health · Status: effective
Cite this
- Citation
- 42 CFR 81.21, § 81.21 Cancers requiring the use of NIOSH-IREP, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/201588
- Permanent ID
ys:prov:201588@1- SHA-256
937f40bd9ebe58ad4be7cd36b4c5bf7c8f808fd857bde23c620e311e2f0ffe10
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) DOL will calculate probability of causation for all cancers using NIOSH-IREP.
(b) Carcinoma in situ (ICD-10-CM codes D00-D09), neoplasms of uncertain behavior (ICD-10-CM codes D37-D44 and D48), and neoplasms of unspecified nature (ICD-10-CM code D49) are assumed to be malignant, for purposes of estimating probability of causation.
(c) All secondary and unspecified cancers of the lymph node (ICD-10-CM codes C77 and C7B.01) shall be considered secondary cancers (cancers resulting from metastasis of cancer from a primary site). For claims identifying cancers of the lymph node, Table 1 in § 81.23(a) provides guidance for assigning a primary site and calculating probability of causation using NIOSH-IREP.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.